Who are ambroxol BIH1526's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): N-acetylcysteine, Hypertonic saline and epinephrine, N-acetylcystein, Acetylcysteine (NAC), Mucolox® alone, Ambroxol Hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ambroxol-bih1526.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ambroxol BIH1526 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ambroxol BIH1526 (ambroxol BIH1526) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mucolytic agent. Area: Respiratory.

phase 3 Mucolytic agent Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

ambroxol BIH1526 (ambroxol BIH1526) — Sanofi. Ambroxol BIH1526 is a mucolytic agent that works by increasing the concentration of glutathione in the airways, which helps to break down and clear mucus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ambroxol BIH1526 TARGET	ambroxol BIH1526	Sanofi	phase 3	Mucolytic agent
N-acetylcysteine	N-acetylcysteine	University of Turin, Italy	marketed	Antioxidant, mucolytic agent	Glutathione synthesis pathway; reactive oxygen species
Hypertonic saline and epinephrine	Hypertonic saline and epinephrine	Le Bonheur Children's Hospital	marketed	Combination bronchodilator and mucolytic agent	Alpha-1 adrenergic receptors, beta-2 adrenergic receptors, osmotic gradient modulation
N-acetylcystein	N-acetylcystein	Assistance Publique - Hôpitaux de Paris	marketed	Antioxidant; mucolytic agent	Glutathione synthesis pathway; free radicals; mucus proteins
Acetylcysteine (NAC)	Acetylcysteine (NAC)	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Mucolytic agent; antioxidant	Glutathione synthesis; disulfide bonds in mucoproteins
Mucolox® alone	Mucolox® alone	University of Alberta	marketed	Mucolytic agent
Ambroxol Hydrochloride	Ambroxol Hydrochloride	National University of Malaysia	marketed	Mucolytic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mucolytic agent class)

GlaxoSmithKline · 1 drug in this class
National University of Malaysia · 1 drug in this class
Sanofi · 1 drug in this class
University College, London · 1 drug in this class
University of Alberta · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ambroxol BIH1526 — Competitive Intelligence Brief. https://druglandscape.com/ci/ambroxol-bih1526. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing